SAN DIEGO, March 8, 2011 /PRNewswire/ — Arena Pharmaceuticals,
Inc. (Nasdaq:
ARNA) today announced it will report fourth quarter and full
year 2010 financial results before the NASDAQ Global Select Market
opens on Friday, March 11, 2011. That same morning, Jack Lief,
Arena’s President and Chief Executive Officer, will host a
conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)
to discuss the financial results for the fourth quarter and full
year 2010 and to provide a business and financial update.
The conference call may be accessed by dialing 877.643.7155 for
domestic callers and 914.495.8552 for international callers. Please
specify to the operator that you would like to join the “Arena
Pharmaceuticals’ Fourth Quarter and Full Year 2010 Financial
Results Call.” The conference call will be webcast live under the
investor relations section of Arena’s website at www.arenapharm.com, and will
be archived there for 30 days following the call. Please connect to
Arena’s website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About Arena PharmaceuticalsArena is a clinical-stage
biopharmaceutical company focused on discovering, developing and
commercializing oral drugs that target G protein-coupled receptors,
an important class of validated drug targets, in four major
therapeutic areas: cardiovascular, central nervous system,
inflammatory and metabolic diseases. Arena’s most advanced drug
candidate is lorcaserin, which is intended for weight management.
Arena’s wholly owned subsidiary, Arena Pharmaceuticals GmbH, has
granted Eisai Inc. exclusive rights to market and distribute
lorcaserin in the United States following FDA approval of the New
Drug Application (NDA) for lorcaserin.
Arena Pharmaceuticals(R) and Arena(R) are registered
serv
‘/>”/>
SOURCE
